Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xenazine data

Xenazine data

Xenazine data
Although Xenazine tetrabenazine met the primary endpoint in the 12-week Phase III TBZ 103,004 study, the compound missed on other outcome

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE